Clinical Trial Update: A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for ES-SCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating Ivonescimab with liposomal irinotecan as second-line therapy for extensive-stage small cell lung cancer; not yet recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• Irinotecan liposome (liposomal irinotecan)
• Ivonescimab (AK112/SMT112)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Extensive-stage Small-cell Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING